Versant’s independent streak

Why Versant is putting Tempest on the path to independence with a $70M series B

With a $70 million series B round, Tempest Therapeutics Inc. marks the first disclosed newco out of Versant Ventures’ Inception Sciences Inc. incubator to stray from the VC’s build-to-buy model.

Versant, F-Prime Capital and Quan Capital led the round, joined by Lilly Asia Ventures,

Read the full 431 word article

User Sign In